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Abstract
Suicidality has been found to be associated with low pre- and postsynaptic
serotonin functioning. The purpose of this study was to examine whether in
acutely suicidal psychiatric inpatients, the blood serotonin concentration was
related to the underlying psychiatric disorder and whether it was associated
with changes in the affinity (dissociation constant, KD) or in the maximal
binding capacity (Bmax) of the platelet serotonin2A receptor. We therefore
determined the blood serotonin concentrations and the platelet serotonin2A
receptor activities of 45 suicidal psychiatric patients and 20 healthy subjects.
We found that the blood serotonin concentrations were significantly lower in
suicidal patients compared to healthy subjects. In all diagnostic categories (af-
fective disorder, schizophrenia and adjustment disorder) we noted a signifi-
cantly higher maximal binding capacity of the platelet serotonin2A receptor.
These findings support the notion that a reduction in the availability of sero-
tonin and an upregulation of the serotonin2A receptors in psychiatric patients
are associated with a loss of control over suicidal impulses.
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Introduction
The disposition to suicidal behavior in psychiatric
patients has been traced to alterations in serotonergic
activity. It has been hypothesized that serotonin and its
receptors function as mediators of control over irrelevant,
distracting and irritating sensory stimulation, regulate im-
pulsivity and influence auto- and heteroaggressive behav-
ior [1, 2]. Thus reduced serotonin availability may be
related to suicidal behavior [for review see 3], in that low
concentrations of 5-hydroxyindoleacetic acid, a metabo-
lite of serotonin in the cerebrospinal fluid (CSF), have
been observed in acutely suicidal patients [4]. An increase
[5–8], but also a decrease [9], was found in the maximal
binding capacity (Bmax) of the serotonin2A receptor in the
postmortem brain tissue of suicide victims, while other
authors observed no change [10–12].
The platelet serotonin content is regarded as an index
of presynaptic serotonin function [13, 14]. Platelets con-
tain most of the biochemical elements of serotonergic
function, comparable to the serotonergic neuron; there-
fore, blood and platelet serotonin concentrations may
serve as a paradigm to assess serotonergic activity. This
agrees with what had previously been observed, namely,
that there was a correlation between the blood serotonin
concentrations and the platelet serotonin2A receptor activ-
ity, and the maximal binding capacity of the serotonin2A
receptor in platelets and the frontal cortex in mammals
and humans [15, 16].
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The aim of the present study was to investigate wheth-
er putative alterations occurred in the blood serotonin
concentration and the Bmax and dissociation constant
(KD) of the platelet serotonin2A receptor in acutely suici-
dal patients compared to healthy controls and whether
these biochemical parameters were related to the patient’s
psychopathological findings.
Subjects and Methods
Subjects
The subjects were 45 suicidal inpatients treated at the Psychiatric
Department of the University of Bonn and 20 healthy volunteers. The
patients were diagnosed by the psychiatric resident and the attending
psychiatrist according to a checklist derived from ICD-10 [17] criteria.
All patients were seen by the same psychiatric resident. Patients
recruited over a 3-year interval for crisis intervention were included in
the study because of acute suicidality during the course of their illness
or after a suicide attempt if they fulfilled the following criteria:
(1) hospitalization due to acute suicidality or (2) presentation within
4 days after a suicide attempt (these criteria were necessary to keep
the patients in a closed ward); (3) availability of psychiatric explora-
tion and blood sampling within 4 days after the suicide attempt;
(4) absence of physical illness; (5) free of antidepressants or of drugs
that interfered with the serotonin parameter measurements such as
clozapine, risperidone, fenfluramine, and at least 2-week use of aspi-
rin; (6) no measurable serum concentrations of SSRI, lithium or tri-
cyclic antidepressants, and (7) no history of alcohol or drug abuse.
Data were available from routine clinical laboratory tests, drug moni-
toring of psychoactive drugs, drug-screening in urine and thrombo-
cyte counts. Criteria 4–7 were applied also to healthy subjects.
Psychopathology was assessed according to the Brief Psychiatric
Rating Scale (BPRS) [18], and the severity of the depressive symp-
toms according to the 21-item Hamilton Depression Rating Scale
(HDRS) [19]; suicidal ideation and severity were rated by the Suicide
Intent Scale (SIS) [20] and anxiety by the Spielberger’s Anxiety Scale
(STAI-G, forms 1 and 2) [21].
The study protocol was in accordance with the Declaration of
Helsinki (revised form, Hong Kong 1989) and was approved by the
Ethics Committee of the Medical Faculty of the University of Bonn.
Patients and healthy subjects were informed on the aims and study
protocols; written consent was obtained from the participants.
Patients’ age ranged from 18 to 59 years, that of the healthy sub-
jects from 18 to 66 years. Patients with affective disorder were some-
what older than patients with adjustment disorder or schizophrenia.
Methods
Blood (50 ml) was obtained from healthy subjects and patients
between 8.00 and 10.00 h and at about the same time of year to avoid
problems arising from circadian and circannual rhythm changes. It
was withdrawn from the antecubital vein of healthy subjects and
patients into vacutainers containing 0.1 ml EDTA (0.38 mol/l) for
each 10 ml of blood. An aliquot of blood for platelet counting was
placed in a Neubauer chamber; the results were validated by external
quality control. Blood was centrifuged within 2 h for 15 min at 200 g
(Minifuge 2, Heraeus Christ, Osterode, Germany) to obtain platelet-
rich plasma. The supernatant was aspirated and centrifuged for 10
min at 2,100 g to obtain platelets. The plasma was carefully aspirated
and the sediment, consisting of platelets, was suspended in buffer I
(5 mmol/l Tris-HCl, containing 0.1% EDTA, pH 7.5) to lyse the
platelets; the suspension was centrifuged for 20 min at 30,000 g. This
procedure was repeated twice. The resulting sediment, which con-
sisted of platelet membranes, was resuspended in buffer II (50 mmol/
l Tris-HCl, pH 7.4, containing 120 mmol/l NaCl, 5 mmol/l KCl, 1
mmol/l MgCl2 and 0.05% ascorbic acid) and stored at –80 °C. Prior
to our assays, the platelet membranes were thawed on ice and homog-
enized in a loose-fitting Potter Elvehjem glass homogenizer (Braun,
Melsungen, Germany). The final protein concentration of the plate-
let membrane preparations was adjusted to 1 mg protein/ml. Protein
was determined according to Lowry et al. [22] using bovine serum
albumin as a standard.
Serotonin2A receptor binding assays were carried out in triplicate
in siliconized glass tubes with 150 Ìl buffer II and 100 Ìl platelet
membrane suspension corresponding to 100 Ìg of protein. The reac-
tion was begun by adding 50 Ìl 3H-LSD; final concentrations ranged
from 0.08 to 5.0 nmol/l corresponding to 1,700–100,000 cpm and the
final volume was 300 Ìl. Nonspecific binding was determined by
replacing 50 Ìl buffer II with ketanserin dissolved in buffer II at a
final concentration of 1 Ìmol/l. Specific binding was the difference
between binding in the absence and presence of ketanserin. Incuba-
tions were done at 37 °C for 3 h and terminated by rapid filtration
over Whatman GF/C filters; the filters were washed twice with ice-
cold buffer II and counted in 5 ml Aquasafe 300 (Zinsser Analytic,
Frankfurt, Germany) in a liquid scintillation beta-counter (Packard
Instruments, Downers Grove, Ill., USA). The binding data were eval-
uated by a modified Marquardt analysis [23, 24]. Experiments with a
correlation coefficient exceeding 0.95 were included in data analysis.
Quality control of the receptor determinations was carried out with
platelets from the same donor (C.F.); the interassay coefficients of
variation for Bmax and KD were 8 and 11%, respectively.
Serotonin was measured by high-performance liquid chromatog-
raphy and electrochemical detection [25]. The intra- and interassay
coefficients of variation were 2.9 and 4.4%, respectively. The lower
limit of detection was 10 nmol/l. The serum was analyzed to check
for antidepressants [26, 27]. Clinical assessment and biological mea-
surements were carried out blindly to each other.
Statistics
Wherever appropriate, data were log-transformed to achieve nor-
mal distribution as ascertained by the Kolmogorov-Smirnov test.
The mean differences in the parameters between healthy subjects
and the three suicidal patient groups were assessed by an ANOVA
and the interaction of age with the biological parameters by an
ANCOVA. For multiple comparisons between items, the least-signif-
icance difference test was performed [28]. Statistical comparisons
between two groups were carried out by the one-tailed nonparametric
Mann-Whitney U test. Spearman rank-order correlations evaluated
the relation between the various parameters. All data presented are
mean B one standard deviation; p ! 0.05 was considered significant-
ly different.
Results
The 51 suicidal patients and 22 healthy subjects eligi-
ble for the study were screened for antidepressant drugs in
blood and recreational drugs in urine; 45 suicidal patients
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Table 1. Demographic and nosological
data of healthy subjects and suicidal
patients (mean B SD)
Healthy
subjects
Patients
adjustment
disorder
affective
disorder
schizophrenia
20 18 16 11
Age, years 31B9b 35B13 45B8a, b 29B7a
BPRS 37B8d 40B8c 54B1c, d
HAMD 22B9 28B7 27B8
SIS 15B9 20B7 20B6
STAI-G 67B8 69B7 66B5
Time after onset (first episode) of
psychiatric symptoms in months 26B73c, d 90B159c 83B70d
For each group, means with common superscript are significantly different: a, b p ! 0.05;
c, d p ! 0.001.
and 20 healthy subjects fulfilled the criteria for entering the
study (table 1). All depressed patients qualified as unipolar
and none of the patients had a history of heteroaggressive
acts. Patients with adjustment disorder were only included
when they were free of axis II pathology according to the
checklist of ICD-10. None of the schizophrenic patients
presented with imperative voices to commit an autoaggres-
sive act. The depressed and schizophrenic patients were
more chronically ill and had a longer hospital residence
than patients with adjustment disorder. The BPRS was
more pronounced in schizophrenic patients than in those
with affective disorder or adjustment disorder. The level of
depression was moderately severe and was highest in
patients with affective disorder, followed by those with
schizophrenia and adjustment disorder, although these dif-
ferences were not statistically significant. The SIS were
similar in patients with schizophrenia and affective disor-
der and somewhat lower, but not statistically significant in
patients with adjustment disorder. None of the suicidal
patients had committed heteroaggressive acts. Sixty-four
percent of these patients were referred to us immediately
after a suicide attempt; 36% were hospitalized on account
of their suicidality in the context of their psychiatric ail-
ment. Thus 22% of the patients with adjustment disorder,
38% of the depressed patients and 33% of the schizophren-
ic patients had never attempted suicide. Of these 45 acutely
suicidal patients, 29 had previously attempted suicide, 18
patients violently and 11 patients nonviolently. There were
no significant differences in the groups with violent and
nonviolent suicide attempts in BPRS, HDRS, STAI-G, age
or sex. Past suicidal history (no previous suicide attempt,
nonviolent or violent suicide attempts) was not related to
the present psychopathology rating.
We found no correlation between age and the seroto-
nergic parameters and no difference between men and
women in their serotonergic parameters in patients or
controls, in agreement with what has previously been
reported [29–32].
Blood serotonin concentrations were lower in the en-
tire suicidal patient group than in healthy subjects (ta-
ble 2). Patients with adjustment disorder had similar
blood serotonin concentrations compared to healthy sub-
jects, but schizophrenic patients and patients with affec-
tive disorder had lower blood serotonin concentrations,
the latter of which contributed mainly to the overall
decrease. The average platelet count was similar in pa-
tient groups and healthy subjects. The Bmax of serotonin2A
receptors was significantly higher in suicidal patients than
in healthy subjects; there was no significant difference
between the three different patient groups, but the Bmax of
each diagnostic category was significantly higher than that
of the healthy subjects (table 2).
The blood serotonin concentration of patients with a
previous suicide attempt (0.80 B 0.29 Ìmol/l, n = 29) and
without a previous suicide attempt (0.80 B 0.42 Ìmol/l,
n = 16) were not significantly different between the two
groups; this applied also to the KD of the serotonin2A
receptor (0.70 B 0.11 nmol/l, n = 29, vs. 0.76 B 0.63
nmol/l, n = 16) and the Bmax of serotonin2A receptors (115
B 40 fmol/mg protein, n = 29, vs. 102 B 34 fmol/mg pro-
tein, n = 16).
The Bmax and KD of serotonin2A receptors were well
correlated in healthy subjects (r = 0.616, p ! 0.0027) and
somewhat less so in suicidal patients, though still signifi-
cant (r = 0.357, p ! 0.05). Blood serotonin correlated sig-
nificantly positively with the affinity (KD) of serotonin2A
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/1
1/
20
17
 3
:5
8:
49
 P
M
Blood serotonin, Ìmol/l
Serotonin2A Receptor and Suicidal Behavior Neuropsychobiology 1998;38:84–89 87
Table 2. Platelet counts and serotonergic parameters of healthy subjects and suicidal patients (mean B SD)
Healthy
subjects
All
patients
Patients
adjustment
disorder
affective
disorder
schizophrenia
0.91B0.19a, b, c 0.80B0.34a 0.91B0.43 0.72B0.25b 0.73B0.23c
Platelet counts, 103/Ìl 227B36 242B72 258B82 240B42 221B88
Serotonin2A-receptor Bmax,
fmol/mg protein 85.9B21.8a, d–f 110.3B38.2a 113.3B34.8d 108.4B34.6e 107.8B50.2f
Serotonin2A-receptor KD, nmol/l 0.49B0.24 0.72B0.55 0.80B0.58 0.58B0.37 0.80B0.72
For each group, means with common superscript are significantly different: a, e, f p ! 0.05; b, c p = 0.09; d p ! 0.01.
receptors in healthy subjects (r = 0.44, p ! 0.05), which
were somewhat less pronounced across all suicidal pa-
tients (r = 0.28, p ! 0.05). There were no significant corre-
lations between the platelet receptor parameters and the
psychopathological scores.
Discussion
Our study shows that platelet serotonergic parameters
differed between acutely suicidal patients and healthy
subjects, suggesting the former had an imbalance in sero-
tonergic activity. These patients had lower blood seroto-
nin than healthy subjects and their Bmax of the serotonin2A
receptor was upregulated.
When we subdivided the suicidal patients according to
diagnosis, we noted a trend toward low blood serotonin in
the schizophrenic patients and in patients with affective
disorder. These data on blood serotonin agree with those
from earlier studies that reported low blood serotonin
concentrations in schizophrenic, schizoaffective and de-
pressed patients who were acutely suicidal or had a histo-
ry of previous suicide attempts [32–35].
The HDRS, STAI-G, and SIS scores were similar
among patients with schizophrenia, affective disorder,
and adjustment disorder. The BPRS scores of schizo-
phrenic patients were higher than those of patients with
affective disorder, but this difference did not seem to play
a role with respect to the biochemical findings, as both
groups had similarly low blood serotonin. Since there was
a significant correlation between the scores from BPRS
and HDRS, HDRS and SIS, BPRS and SIS (data not
shown), we studied the graphs of this correlation analysis
but found no clustering of items with respect to any diag-
nostic category. However, the low variance in serotoner-
gic parameters precluded any meaningful correlation be-
tween the above psychopathological ratings. To elucidate
whether any previous suicidal history influenced biologi-
cal parameters, we subdivided patients into those with no
previous suicide attempt(s), nonviolent suicide attempts
and violent suicide attempts; again there was no signifi-
cant difference between these three groups with respect to
blood serotonin concentration or to Bmax and KD of the
serotonin2A receptor, nor was there any association be-
tween the patients’ previous suicidal history and any of
the biological parameters. Previously, in a group of
nonsuicidal and suicidal depressed patients, an inverse
correlation had been noted between platelet serotonin and
suicidal behavior [32]. However, subdividing our patients
into suicide attempters and nonattempters revealed no
differences, either in the biological parameters or in the
psychopathological rating scores. Similar observations
were reported by Meltzer and Arora [36], who neither
observed differences in the platelet serotonin content of
suicide attempters and nonattempters nor in the platelet
serotonin content of those with a history of violent and
nonviolent suicide attempts.
Psychiatric patients showed distinct fluctuations in
blood serotonin concentrations that were associated with
fluctuations in their psychopathology; these fluctuations
were most pronounced within several days after a suicide
attempt, when very low blood serotonin concentrations
rose in individual patients up to 70-fold, but were still low
compared to those of healthy subjects [35]. Therefore we
attributed changes in serotonin turnover to suicidal im-
pulses. For the sake of homogeneity in the patient popula-
tion, only acutely suicidal patients were included in the
present study; apparently we were dealing with self-
directed aggressive behavior, since none of the patients
committed a heteroaggressive act.
The question is whether there is an association be-
tween low blood serotonin and depression or schizophre-
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nia in nonsuicidal psychiatric patients. Previous studies
found no differences in the blood serotonin of nonsuicidal
schizophrenic or schizoaffective patients when compared
to healthy subjects [33, 34, 37], but high blood serotonin
levels [30, 38, 39] were also noted; no difference in blood
or platelet serotonin concentrations was reported between
nonsuicidal unipolar depressed and healthy subjects [30,
36, 40–43]. The suicidal depressed and schizophrenic
patients of our study were more chronically ill than
patients with adjustment disorder; therefore both chro-
nicity and suicidal behavior may be associated with the
altered serotonergic function in these patients.
Across all the diagnostic groups of our acutely suicidal
patients the serotonin2A receptor’s Bmax was higher than in
healthy subjects. The Bmax of the platelet serotonin2A
receptor was significantly higher in depressed patients
with suicidal ideation and in suicide attempters than in
nonsuicidal depressed patients or in healthy subjects [36,
44–46].
In healthy subjects a positive correlation was noted ear-
lier between the KD and the Bmax of the serotonin2A recep-
tor [15]. In addition, in all subjects platelet serotonin regu-
lated the affinity of the serotonin2A receptor, thus a higher
serotonin availability was associated with a reduction in
the serotonin2A receptor affinity, i.e., an increase in the KD
[15]. However, it may be noted that the correlation was
better in healthy subjects than in suicidal patients, suggest-
ing reactions that interfered with a putative regulatory pro-
cess in these patients. The mechanism underlying the
observed correlation between blood serotonin concentra-
tion and the KD is presently unknown. Direct competition
between serotonin derived from the platelet membranes
and 3H-LSD for the binding at the receptor site is unlikely,
as shown by us previously [15], since serotonin, which is
hydrophilic, is washed out during the preparation of the
membranes by more than 99.5% giving rise to less than
5 nM endogenous serotonin in the incubation mixture.
This is too low to interfere with the 3H-LSD binding.
In the present study a trend toward a decrease in whole
blood serotonin pertained to patients with depression and
schizophrenia. The narrow range of serotonin concentra-
tions in these subjects precluded a meaningful correlation
between Bmax and blood serotonin. Our findings, and that
of others [36, 44, 46, 47], of an increase in the Bmax of the
serotonin receptor and serotonin receptor function in
platelets [48] suggest a compensatory reaction elicited by
low blood and platelet serotonin levels in acutely suicidal
patients.
The biological markers of serotonergic function appear
to be closely correlated to impulsivity, aggression and vio-
lent suicidal behavior across broad diagnostic categories;
neuroendocrine challenge tests with 5-hydroxytryptophan
[49] or fenfluramine [50; for review see 51] suggest a
reduced central serotonergic function in these types of
mood disorder which may not be specific but could be
related to suicidal behavior. It is generally accepted that
the blood-brain barrier singles out the way bioactive mol-
ecules are exchanged between the central nervous system
(CNS) and the periphery; these findings do not rule out
the possibility that receptor sites present in the CNS and
periphery share similar properties. In fact the serotonin2A
receptors in the brain and in platelets are structurally
identical [52]. In adolescent schizophrenic inpatients a
negative correlation between the maximal velocity of
platelet serotonin uptake and aggressive behavior includ-
ing suicide attempts has been reported [53], which agrees
with the finding of Meltzer and Arora [36] of a dimin-
ished activity of the platelet serotonin transport in adult
patients with high suicide ratings. Thus reduced trans-
porter activity may be related to the low blood serotonin
concomitant with the upregulation of the serotonin2A
receptor activity that we noted in our suicidal patients.
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